Xian Janssen Pharmaceutical Ltd. announced that the China Food and Drug Administration (CFDA) has approved SIRTURO® (bedaquiline) for use as part of combination therapy in adult patients (18 years and older) with pulmonary multidrug-resistant TB (MDR-TB).
